Swedbank AB Has $7.11 Million Position in Natera, Inc. $NTRA

Swedbank AB cut its position in Natera, Inc. (NASDAQ:NTRA) by 6.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,080 shares of the medical research company’s stock after selling 3,055 shares during the quarter. Swedbank AB’s holdings in Natera were worth $7,109,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in NTRA. Bank of Jackson Hole Trust acquired a new position in shares of Natera in the 1st quarter valued at approximately $29,000. Rakuten Securities Inc. boosted its stake in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock valued at $31,000 after buying an additional 119 shares in the last quarter. ORG Partners LLC acquired a new stake in Natera in the first quarter valued at about $32,000. TCTC Holdings LLC boosted its stake in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after buying an additional 124 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after buying an additional 106 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the sale, the director owned 6,015 shares in the company, valued at $1,004,444.85. This represents a 31.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 5,079 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $166.53, for a total transaction of $845,805.87. Following the completion of the sale, the chief executive officer owned 158,514 shares of the company’s stock, valued at approximately $26,397,336.42. This represents a 3.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,423 shares of company stock valued at $8,459,656 over the last 90 days. 5.63% of the stock is currently owned by company insiders.

Natera Trading Up 0.7%

Natera stock opened at $181.11 on Monday. The firm’s fifty day moving average price is $156.80 and its two-hundred day moving average price is $155.19. The firm has a market capitalization of $24.86 billion, a price-to-earnings ratio of -94.82 and a beta of 1.68. Natera, Inc. has a 1-year low of $117.27 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NTRA. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price objective for the company in a research report on Monday, July 28th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Cowen reiterated a “buy” rating on shares of Natera in a research report on Friday, August 8th. Morgan Stanley reiterated an “overweight” rating and set a $195.00 price objective on shares of Natera in a research report on Sunday, August 10th. Finally, Piper Sandler reiterated an “overweight” rating and set a $220.00 price objective (up from $210.00) on shares of Natera in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company. According to MarketBeat.com, Natera has a consensus rating of “Buy” and a consensus price target of $194.00.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.